IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.07
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.064

19 Jul
2024

-0.006

OPEN

$0.07

-8.57%

HIGH

$0.07

4,377,162

LOW

$0.06

TARGET
$0.181 182.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx - 1.1 - 1.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-1.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx11.3 M
Book Value Per Share xxxxxxxxxxxxxxx3.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-18.0 M
Net Profit Margin xxxxxxxxxxxxxxx-180.90 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-36.67 %
Return on Invested Capital xxxxxxxxxxxxxxx-36.30 %
Return on Assets xxxxxxxxxxxxxxx-32.21 %
Return on Equity xxxxxxxxxxxxxxx-36.67 %
Return on Total Capital xxxxxxxxxxxxxxx-40.24 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-18.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx3 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx46 M
Price To Book Value xxxxxxxxxxxxxxx5.97

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx6.0 M
Capex % of Sales xxxxxxxxxxxxxxx53.27 %
Cost of Goods Sold xxxxxxxxxxxxxxx25 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx9 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

01/05/2024

1

Speculative Buy

$0.16

150.00%

The regulatory and funding frameworks underpinning ImpediMed’s US commercialisation pathway continue to strengthen, Ord Minnett notes, and new management is pulling the right levers to position the business for material growth from FY25 onwards.

With the positive impacts from realigning the sales team initiatives and critical mass reimbursement in their infancy, March Q US SOZO sales, while disappointing, were not unexpected.

Ord Minnett expects an acceleration in US installed base growth in the first half FY25, with payor updates and potential multi-site Integrated Delivery Network contracts looming as nearer term catalysts.

Speculative Buy and 16c target retained.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -1.00 cents.
Ord Minnett forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.70 cents.

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

12/03/2024

1

Buy

$0.14

118.75%

ImpediMed's 1H results were in line with the 2Q trading update. As Canaccord Genuity expected, revenue growth was weak and the broker suggests the recent fall in share price is overdone as progress adding payors and critical mass states has been solid.

The analyst believes Sozo's launch trajectory should be viewed positively as a land grab with new management taking a structured approach to focusing on the growth opportunity.

Canaccord's target falls to 14c from 18c due to the impact of a slower-than-expected sales cycle. The Buy rating is unchanged.

FORECAST
Canaccord Genuity forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -1.30 cents.
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.10 cents.

Taylor Collison

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

IPD STOCK CHART